-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse NYSE New York Stock ExchangeEURISIN DK0060534915-
Novo Nordisk A/SBörse Börse FrankfurtEURSymbol NOVC
-
Novo Nordisk A/SBörse Börse FrankfurtEURSymbol NOVA
-
Novo Nordisk A/SBörse Börse MünchenEURSymbol NOVA
-
Novo Nordisk A/SBörse Börse MünchenEURSymbol NOVC
-
Novo Nordisk A/SBörse Börse BerlinEURSymbol NOVC
-
Novo Nordisk A/SBörse Börse BerlinEURSymbol NOVA
-
Novo Nordisk A/SBörse Börse DüsseldorfEURSymbol NOVA
-
Novo Nordisk A/SBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol NOVA
-
Novo Nordisk A/SBörse Quotrix System der Börse DüsseldorfEURSymbol NOVA
-
Novo Nordisk A/SBörse Börse StuttgartEURSymbol NOVA
-
Novo Nordisk A/SBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol NOVC
-
Novo Nordisk A/SBörse Börse StuttgartEURSymbol NOVC
-
Novo Nordisk A/SBörse Gettex System der Börse MünchenEURSymbol NOVC
-
Novo Nordisk A/SBörse Quotrix System der Börse DüsseldorfEURSymbol NOVC
-
Novo Nordisk A/SBörse Börse DüsseldorfEURSymbol NOVC
-
Novo Nordisk A/SBörse Gettex System der Börse MünchenEURSymbol NOVA
-
Novo Nordisk A/SBörse Börse Stuttgart
-
Novo Nordisk A/SBörse Börse Stuttgart
-
Novo Nordisk A/S ADRBörse NYSE New York Stock ExchangeISIN US6701002056 WKN: 866931USDSymbol NVO
-
NOVO NORDISK A/S-BBörse Amerikanscher Freiverkehr OTC oder "Pink Sheets"ISIN DK0060534915 WKN: A1XA8RUSDSymbol NOVOB
-
Novo Nordisk A/S BBörse NYSE New York Stock ExchangeISIN DK0060534915 WKN: A1XA8REURSymbol NOVO-B
-
NOVO NORDISK A/S-BBörse Amerikanscher Freiverkehr OTC oder "Pink Sheets"USDSymbol NOVC
-
Novo Nordisk A/S BBörse OMXC Copenhagen Stock ExchangeISIN DK0060534915 WKN: A1XA8RSymbol NOVO B
-
ISIN DK0060534915
-
MXN
-
Symbol NOVC
-
Symbol NOVA
-
Novo NordiskBörse London Stock Exchange
-
Novo Nordisk A/SBörse Freiverkehr OTC
-
ISIN DK0060534915
WKN A1XA8R
Symbol NOVO-B
Währung
EUR
Börse
NYSE New York Stock Exchange
Portrait der Novo Nordisk Aktie
Das Unternehmen Novo Nordisk aus Dänemark ist in den Bereichen Chemie & Pharma, Einzelhandel (Medikamente), Einzelhandel, Pharma tätig.
Novo Nordisk ist in mehr als 64 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter iShares STOXX Europe 600 Health Care UCITS ETF (DE) gewichtet Novo Nordisk mit 9,30% im ETF.
Entdecke die 6 ETFs in denen Novo Nordisk am höchsten gewichtet ist Insgesamt in 64 ETFs enthalten
Dir gefallen die Informationen zu Novo Nordisk?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Novo Nordisk?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Novo Nordisk?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Novo Nordisk?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
110 News & Informationen zur Novo Nordisk Aktie
Global $5.42 Bn Anti-Obesity Drugs Markets to 2030: Focus on Prescription Drugs (Rx), OTC Drugs, Monotherapies, & Polytherapies
/PRNewswire/ — The
Global $5.42 Bn Anti-Obesity Drugs Markets To 2030: Focus On Prescription Drugs (Rx), OTC Drugs, Monotherapies, & Polytherapies
DUBLIN, Aug. 31, 2021 /PRNewswire/ — The “Antiobesity Global Market Report 2021: COVID-19 Impact and Recovery to 2030” report has been added to
Innate Pharma : to Participate in Upcoming Investor Conferences
Marseille, France, Aug. 30, 2021 — Innate Pharma SA today announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor… | August 30, 2021
The Ten Top Miscellaneous Region Funds
We have used the past one year return data (from U.S. News) to come up with the list of ten top Miscellaneous Region funds.
Global Antidiabetic Drug Market Report 2021-2026 – Opportunities in New Innovations
/PRNewswire/ — The “Global Antidiabetic Drug Market (2021-2026) by Drug Type, Diabetic Type, Patient, Geography, Competitive Analysis and the Impact of…
Logan Capital Management Inc Buys OneMain Holdings Inc, TTEC Holdings Inc, Morgan Stanley, Sells Verisk Analytics Inc, PayPal Holdings Inc, State Street Corporation
GuruFocus Article or News written by insider and the topic is about:
Anchor Capital Advisors Llc Buys CarGurus Inc, Royal Gold Inc, Clorox Co, Sells CDK Global Inc, Haemonetics Corp, Verizon Communications Inc
GuruFocus Article or News written by insider and the topic is about:
Prio Wealth Limited Partnership Buys CME Group Inc, Nike Inc, Vanguard Small Cap ETF, Sells General Electric Co, , Bryn Mawr Bank Corp
GuruFocus Article or News written by insider and the topic is about:
Home-Use Insulin Delivery Devices Market to Hit $19,087.6 Million Revenue by 2030 says P&S Intelligence
NEW YORK, Aug. 18, 2021 /PRNewswire/ — From $7,276.9 million in 2020, the size of the global home-use insulin delivery devices market will increa…
Home-Use Insulin Delivery Devices Market to Hit $19,087.6 Million Revenue by 2030 says P&S Intelligence
/PRNewswire/ — From $7,276.9 million in 2020, the size of the global home-use insulin delivery devices market will increase to $19,087.6 million in 2030, at a…
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc. (NYSE: BIO) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) Gilead Sciences, Inc. (NASDAQ: GILD) GlaxoSmithKline plc (NYSE: GSK) Johnson & Johnson (NYSE: JNJ) Laboratory Corporation of America Holdings (NYSE: LH) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) NanoVibronix, Inc. (NASDAQ: NAOV) (announced intention to enter over-
Major Depressive Disorder Therapeutic Market Size Expected to Witness Growth at a CAGR of 8.91% for the Study Period 2018-2030 | DelveInsight
/PRNewswire/ — DelveInsight's Major Depressive Disorder Market report offers detailed information on current treatment practices, emerging drugs, Major…
Major Depressive Disorder Therapeutic Market Size Expected to Witness Growth at a CAGR of 8.91% for the Study Period 2018-2030 | DelveInsight
/PRNewswire/ — DelveInsight's Major Depressive Disorder Market report offers detailed information on current treatment practices, emerging drugs, Major…
Major Depressive Disorder Therapeutic Market Size Expected to Witness Growth at a CAGR of 8.91% for the Study Period 2018-2030 | DelveInsight
/PRNewswire/ — DelveInsight's Major Depressive Disorder Market report offers detailed information on current treatment practices, emerging drugs, Major…
Major Depressive Disorder Therapeutic Market Size Expected to Witness Growth at a CAGR of 8.91% for the Study Period 2018-2030 | DelveInsight
/PRNewswire/ — DelveInsight's Major Depressive Disorder Market report offers detailed information on current treatment practices, emerging drugs, Major…
Major Depressive Disorder Therapeutic Market Size Expected to Witness Growth at a CAGR of 8.91% for the Study Period 2018-2030 | DelveInsight
/PRNewswire/ — DelveInsight's Major Depressive Disorder Market report offers detailed information on current treatment practices, emerging drugs, Major…
Major Depressive Disorder Therapeutic Market Size Expected to Witness Growth at a CAGR of 8.91% for the Study Period 2018-2030 | DelveInsight
/PRNewswire/ — DelveInsight's Major Depressive Disorder Market report offers detailed information on current treatment practices, emerging drugs, Major…
Global Weight Loss Products And Services Market Report 2021: The Business Of Weight Loss In The 20th And 21st Centuries
DUBLIN, Aug. 13, 2021 /PRNewswire/ — The
Top Research Reports for Berkshire Hathaway, Cisco & Novo Nordisk
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Cisco Systems, Inc. (CSCO), and Novo Nordisk A/S (NVO).
Walmart preview: U.S. sales growth at Walmart could outdo Amazon
Walmart's grocery business is gaining strength as shoppers become more price sensitive, analysts say
LRT Capital on Novo Nordisk (NVO): “We Believe this to be Highly Attractive”
LRT Capital Management, an investment management firm, published its second-quarter 2021 investor letter – a copy of which can be downloaded here.
Were Hedge Funds Right About Danaher Corporation (DHR)?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second …
Maersk’s green shipping plan runs up against scarce cooking oil
Maersk consumes about 12 million tons of marine oil per year, roughly equal to all the oil produced in the world in one day.
Novo Nordisk A/S (NVO) Q2 2021 Earnings Call Transcript
NVO earnings call for the period ending June 30, 2021.
Global Pediatric Vaccine Market Research Report 2021: Market is Expected to Reach $49.9 Billion in 2025 – Long-term Forecast to 2030
/PRNewswire/ — The
Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q2 2021 Results – Earnings Call Transcript
Novo Nordisk A/S (NYSE:NVO) Q2 2021 Earnings Conference Call August 4, 2021 1:00 PM ET Company Participants Lars Fruergaard Jørgensen – President & Chief Executive Officer Karsten Munk…
Novo Nordisk A/S 2021 Q2 – Results – Earnings Call Presentation (NYSE:NVO)
The following slide deck was published by Novo Nordisk A/S in conjunction with their 2021 Q2 earnings call.